Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
HOME > COMMENTARY
COMMENTARY
-
Key Figures in Next Drug Pricing Reform Now All in Place, In What Direction Will They Go for Pro-Innovation Drive?
November 15, 2023
-
Predicting Clinical, Financial Impact of Hemophilia Gene Therapy in Japan
November 7, 2023
-
Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing
October 31, 2023
-
With 2nd Strategy Penned, Can Japan Play Catch-Up with US & Europe in SaMD Push?
October 3, 2023
-
Hopes to Nix Budget Ceiling Dashed, How Will Industry Get Its Message Across to Govt?
September 4, 2023
-
Chuikyo Embracing Industry Opinions in Early Phase of Drug Pricing Debate
August 29, 2023
-
Can “G1” Withdrawal Scheme Be Improved Enough to Serve Its Purpose?
August 23, 2023
-
Study Group of LDP Heavyweights Eyes “Drug Discovery Agency”
August 7, 2023
-
Expert Panel Report Failed to Delve into Annual Price Cuts, Irking Pharma Officials
June 30, 2023
-
Honebuto Policy Is Tailwind for Pharma, but Situation Remains Unpredictable
June 22, 2023
-
Will Wegovy Lead the Way in Changing Picture of Obesity Treatment in Japan?
May 23, 2023
-
Will Bill to Amend Medical Infrastructure Law Accelerate Drug Discovery for Rare Diseases?
April 28, 2023
-
Some Pharma Makers Leery of Further Cut into Off-Patent Brands in Japan
April 3, 2023
-
Revision of Guidelines on Drone Drug Deliveries Expected by March-End: Will Powerful Meds Be OK'ed?
March 17, 2023
-
FY2024 Pricing Reform Likely to Focus on “Balance” between Rewarding Innovation and Optimizing LLP Prices
February 6, 2023
-
LDP Expects to Finalize Tax Reform Plan This Week; Will It Expand R&D Credit System?
December 13, 2022
-
Japan Should Hone Emergency Approval Scheme Based on Xocova Example
November 28, 2022
-
Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
November 22, 2022
-
Pharma Industry Faces Hurdles in Getting Medical Circle to Accept Softer Drug Price Cut Plan
September 28, 2022
-
Delving into Potential Implications of Envisaged Price Revision Overhaul
September 12, 2022
